Coronavirus Vaccine Market, By Vaccine Type (Inactivated Virus, Protein Subunit, Non-replicating Viral Vector, Repurposed Vaccines, RNA vaccine, DNA vaccine), By Distribution Channel (Government Channels, Hospitals, Clinics, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Oct 2023

Code : CMI4320

Pages :170

Formats :

Excel and PDF

Industry : Pharmaceutical

Regional Analysis

Global Coronavirus Vaccine Market - Regional Analysis

Among region, North America is expected to hold dominant position in the global coronavirus vaccine market over the forecast period due to increasing number of product launches and approvals associated with coronavirus vaccine by regulatory bodies. For instance, on December 18, 2021, Moderna, Inc., a biotechnology company, received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for mRNA-1273, a COVID-19 vaccine that is indicated for preventing COVID-19 in individuals of age of 18 years and above. Moreover, market players are focusing on agreements and collaborations to meet the increasing demand for COVID-19 vaccines in the region, and this is expected to boost the coronavirus vaccine market growth in North America region. For instance, on February 02, 2021, Ocugen, Inc., a U.S.-based biopharmaceutical company, entered into a definitive agreement with Bharat Biotech, a Inida based global pharmaceutical company, to co-develop, supply, and commercialize COVAXIN, a COVID-19 vaccine developed by Bharat Biotech, in the U.S. market.
Market players are focusing on obtaining approval for COVID-19 vaccine from regulatory authorities, and this is expected to drive the market growth in Europe region over the forecast period. For instance, on March 18, 2020, Pfizer Inc. and BioNTech SE, A collaboration of two U.S. based multinational pharmaceutical company, announced receiving of conditional marketing authorization (CMA) from the European Commission (EC) for COMIRNATY, a COVID-19 vaccine. On January 6, 2021, Moderna, Inc., a global pharmaceutical company, received conditional marketing authorization (CMA) from the European Commission for the COVID-19 vaccine namedModerna.

Geographies covered:

North America: U.S. and Canada
Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
Middle East: GCC, Israel, and Rest of Middle East
Africa: South Africa, North Africa, and Central Africa